Fouad Namouni, MD
The Japanese Ministry of Health, Labor and Welfare has approved nivolumab (Opdivo) for the treatment of patients with unresectable advanced or recurrent esophageal cancer that has progressed following chemotherapy.1
ATTRACTION-3 builds on the phase II ATTRACTION-1 study that showed that nivolumab had promising antitumor activity with a manageable safety profile with advanced ESCC refractory to or intolerant of standard chemotherapies.3
ATTRACTION-3 enrolled 419 patients with unresectable advanced or recurrent ESCC refractory to or intolerant of 1 prior fluoropyrimidine/platinum-based chemotherapy. They were randomized in a 1:1 ratio to nivolumab at 240 mg intravenously every 2 weeks, or investigator’s choice of taxane chemotherapy that consisted of either docetaxel at 75 mg/m2
intravenously every 3 weeks, or paclitaxel at 100 mg/m2
intravenously every week for 6 weeks, then 1 week off.
... to read the full story